Detalhe da pesquisa
1.
Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.
CA Cancer J Clin;
70(6): 480-504, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32910493
2.
Use of new and emerging cancer drugs: what the cardiologist needs to know.
Eur Heart J;
2024 Apr 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38591670
3.
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer.
Breast Cancer Res Treat;
2024 May 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38771399
4.
Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: The CROWN study.
Am Heart J;
267: 33-43, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37890547
5.
Coverage for evidence-based cancer survivorship care services.
Support Care Cancer;
32(3): 165, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38368466
6.
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association.
Circulation;
145(15): e811-e838, 2022 04 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35249373
7.
Social Determinants of Health and Racial Disparities in Cardiac Events in Breast Cancer.
J Natl Compr Canc Netw;
21(7): 705-714.e17, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37433439
8.
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
CA Cancer J Clin;
66(4): 309-25, 2016 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26919165
9.
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis.
Eur Heart J;
43(4): 300-312, 2022 Jan 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34791123
10.
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
Eur Heart J;
43(4): 280-299, 2022 01 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34904661
11.
Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association.
Circulation;
144(3): e41-e55, 2021 07 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34134525
12.
Cardiometabolic Consequences of Targeted Anticancer Therapies.
J Cardiovasc Pharmacol;
80(4): 515-521, 2022 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34654781
13.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat;
189(3): 689-699, 2021 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34414532
14.
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.
Curr Oncol Rep;
23(11): 128, 2021 08 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34453232
15.
The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic.
Curr Oncol Rep;
23(8): 99, 2021 07 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34259950
16.
Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial.
BMC Fam Pract;
22(1): 234, 2021 11 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34794388
17.
Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.
Circulation;
137(8): e30-e66, 2018 02 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29437116
18.
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J;
43(41): 4229-4361, 2022 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36017568
19.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat;
191(1): 223-224, 2022 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34625861
20.
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
Breast Cancer Res Treat;
157(1): 109-16, 2016 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27116183